Project Grant R00HL163519
Award Date
6/2/25
Completion Date
5/31/28
Dollars Obligated
$249K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837) to Brigham & Women's Hospital Inc. to conduct research focused on understanding the heterogeneity and endotypes of asthma. The $177,403 award, with an effective date of Sep 1, 2024 and an ultimate completion date of Aug 31, 2029, will leverage multi-omics data to investigate the genetic, epigenetic, and metabolomic factors underlying...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $177,721 to Brigham & Women's Hospital Inc. for a 5-year research project starting on September 1, 2024. The project, led by Principal Investigator Dr. Nicole Prince, aims to apply molecular epidemiology approaches to improve understanding of the biological determinants underlying respiratory infection risk, a leading cause of...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $616,814 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Harvard T.H. Chan School of Public Health to conduct research on the role of microRNAs in regulating airway smooth muscle function and their impact on asthma. The overarching goal is to establish the in vivo function of key microRNAs in regulating airway smooth muscle properties and airway hyperresponsiveness, as well as to determine how...
This federal Project Grant award of $915,924.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate how disruptions to the infant lung microbiome can impact the development and function of lung-resident immune cells and epithelial cells, leading to long-term pulmonary health issues. The key objectives are to: 1) examine how perinatal microbial dysbiosis affects the accrual and fate of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $816,358 to Vanderbilt University Medical Center (VUMC) to investigate the impact of infant antibiotic exposure on the development of the airway and gut microbiome, and the risk of childhood asthma. The key goals are to: 1) determine the age when infants are most susceptible to the harmful effects of antibiotics on asthma risk, 2)...
This federal Project Grant award of $565,250 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support a longitudinal study to characterize the effect of host-microbiome interactions on pulmonary function in adults with and without HIV in Botswana. The study will incorporate advanced multi-omic techniques, including shotgun metagenomic sequencing, host transcriptomics, and untargeted metabolomics, to analyze...
This $355,935 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the development of a novel, oral immunoregulatory therapeutic for the treatment of asthma by Biotherapeutics, Inc., an emerging biotechnology company in Blacksburg, Virginia. The project aims to characterize the therapeutic efficacy and route of administration of the novel immunoregulatory compound in mouse models...
This $641,544 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports the development of novel machine learning methods to address key challenges in analyzing complex biomedical data related to heart, lung, blood, and sleep (HLBS) disorders. Specifically, the project aims to: 1) propose new machine learning techniques for uncovering causal relationships between clinical...
This federal Project Grant award, totaling $521,214.63, was issued by the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), to Rutgers, The State University of New Jersey. The 3-year grant, starting on July 1, 2024, aims to investigate the methylomic and metabolomic determinants of lung function in children with asthma. The research will integrate genomic, epigenomic, and metabolomic data from three large prospective childhood...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $834,840 to Brigham & Women's Hospital Inc. to conduct research on emulating hypothetical randomized trials to establish the comparative effectiveness of biologic treatments for severe asthma. The project aims to leverage the team's clinical expertise in asthma and monoclonal antibody research, along with advanced causal...